Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Net Income (2016 - 2025)

Traws Pharma (TRAW) has disclosed Net Income for 14 consecutive years, with -$7.4 million as the latest value for Q4 2025.

  • For Q4 2025, Net Income fell 39.6% year-over-year to -$7.4 million; the TTM value through Dec 2025 reached -$17.9 million, up 87.45%, while the annual FY2025 figure was -$17.9 million, 87.45% up from the prior year.
  • Net Income hit -$7.4 million in Q4 2025 for Traws Pharma, down from -$4.1 million in the prior quarter.
  • Across five years, Net Income topped out at -$1.2 million in Q2 2025 and bottomed at -$123.3 million in Q2 2024.
  • Average Net Income over 5 years is -$10.8 million, with a median of -$4.9 million recorded in 2021.
  • Year-over-year, Net Income tumbled 2575.66% in 2024 and then soared 98.99% in 2025.
  • Traws Pharma's Net Income stood at -$3.8 million in 2021, then tumbled by 52.38% to -$5.7 million in 2022, then grew by 22.18% to -$4.5 million in 2023, then dropped by 18.29% to -$5.3 million in 2024, then plummeted by 39.6% to -$7.4 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at -$7.4 million, -$4.1 million, and -$1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.